Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients.
The effect of naproxen on heterotopic ossification after total hip replacement was studied in a randomized, double-blind trial. Twenty-eight patients received 250 mg naproxen thrice daily for 4 weeks postoperatively starting on the morning of the operation while 27 control patients received a placebo. Three months after the operation, 13 patients in the control group had heterotopic ossification compared with 4 patients in the group that received naproxen; and after 1 year, the figures were 15 and 4, respectively (P less than 0.01). Three control patients had severe ossifications. We conclude that naproxen given for 4 weeks is sufficient to decrease the incidence of heterotopic ossification after cemented total hip replacement.
Gebuhr
P
P
Department of Orthopedics, Hvidovre University Hospital, Denmark.
Soelberg
M
M
Orsnes
T
T
Wilbek
H
H
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D006622:Hip Prosthesis / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D009288:Naproxen / Q000008:administration & dosage / Q000627:therapeutic use*; D009999:Ossification, Heterotopic / Q000209:etiology / Q000517:prevention & control*; D011182:Postoperative Care; D011300:Preoperative Care; D011446:Prospective Studies; D013488:Suppositories; D013997:Time Factors
D013488:Suppositories; D009288:Naproxen